— Bnip3-KO mice: These were generated by replacing exons 2 and 3 with a neomycin resistance cassette. Recombinations were identified via southern blot.
Publication: Inhibition of ischemic cardiomyocyte apoptosis through targeted ablation of Bnip3 restrains postinfarction remodeling in mice
Nix KO m…
— WUSTL Technology 016481
Technology Description
Researchers at Washington University in St. Louis have developed an additional targeting strategy to provide more flexibility and improve the bioactivity of the anticancer therapeutic TR3. This strategy targets TR3 to mesothelin, a tumor biomarker fr…
— WUSTL Technology 011885
Technology Description
Researchers at Washington University in St. Louis have developed a strategy to specifically target the anticancer therapeutic TR3 to cancer cells using the mesothelin/MUC16 interaction. Mesothelin is a GPI linked cell surface protein expressed in mes…
— WUSTL Technology 007646
Technology Description
Researchers at Washington University in St. Louis (WUSTL) have developed a novel TRAIL (TNF-related apoptosis inducing ligand)-based anticancer drug platform, designated TR3. TRAIL has potent and specific apoptotic activity against tumor cells. Thus,…
— Target: T Cell Immunoreceptor with Ig and ITIM domains, a.k.a. WUCAM
Notes: Clone available is 4E1.2. Used in flow cytometry and functional studies.
Publication: A novel molecular interaction for the adhesion of follicular CD4 T cells to follicular DC
| Name | # Summaries | Author |
|---|---|---|
| 15 | ||
| 13 | ||
| 15 | ||
| 26 | ||
| 14 | ||
| 14 |
Creating...
